Janssen Scientific Affairs, LLC
167
19
37
89
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
19.2%
32 terminated/withdrawn out of 167 trials
73.6%
-13.0% vs industry average
28%
46 trials in Phase 3/4
65%
58 of 89 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (167)
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
Role: lead
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
Role: collaborator
Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy
Role: collaborator
Wellness & Workforce Solution for Lupus/Lupus Nephritis
Role: collaborator
Optimized Erythropoietin (EPO) Treatment
Role: collaborator
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
Role: collaborator
Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
Role: collaborator
Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial
Role: collaborator
Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer
Role: collaborator
Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
Role: collaborator
Psoriasis Longitudinal Assessment and Registry
Role: lead
Efficacy of Guselkumab in Treating Hailey Hailey Disease
Role: collaborator
Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Role: collaborator
Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy
Role: collaborator
Immune Spatial Features of Guselkumab Cutaneous Response
Role: collaborator
Sequential Therapy in Multiple Myeloma Guided by MRD Assessments
Role: collaborator
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
Role: collaborator
Guselkumab for Overlap Inflammatory Bowel Disease and Spondyloarthritis
Role: collaborator
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
Role: collaborator
High-Risk Metachronous Oligometastatic Prostate Cancer Trial
Role: collaborator